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Abstract 
The coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV2) that first appeared in Wuhan, China. 
COVID-19 was found to have significant implications on the cardiovascular system. This is 
depicted by several manifestations such as myocardial injury, malignant arrhythmias, 
complicating the management of acute coronary syndrome, and even cardiogenic shock.  
Worse, the medications for COVID-19 had been known to induce cardiovascular side effects 
and had drug-drug interaction with anticoagulants. RAS blocker, as the holy grail of 
hypertension and heart failure medication, should also be continued despite COVID-19 
infection.  
Keywords: COVID-19, cardiovascular implications, medications 
 
Introduction 
Coronavirus disease-2019 (COVID-19) is an infectious disease caused by severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV2) that first appeared in Wuhan, China.1,2 
SARS-CoV2 rapidly spread to almost every country in the world and COVID-19 was declared 
a pandemic by the World Health Organization on 11 March 2020.2 In Indonesia, COVID-19 
has affected 11.192 confirmed patients with 1.871 patients recovered and 845 patients deceased 
(4 May 2020).3 A cohort study found that comorbidities present in COVID-19 patients include 
hypertension (30%), diabetes (19%), coronary heart disease (8%), chronic obstructive lung 
disease (3%), carcinoma (1%), and chronic kidney disease (1%).4 While in a large study of 
44672 COVID-19 patients also in China, those with cardiovascular disease comprised 22.7% 
of all fatal cases.2 Another study in 138 hospitalized COVID-19 patients found that the most 
common causes of admittance to ICU among 36 patients were ARDS (61%), arrhythmias 
(44%), and shock (31%).5 
 
 
CARDIOVASCULAR SEQUELAE AND TREATMENT CHALLENGES in COVID-19 
PATIENT 
 
Myocardial Injury in COVID-19 Infection 
Myocardial injury happens in 7 to 28 percent of hospitalized patients with COVID-19 
infection and related to poor prognosis.10,11 Patient with myocardial injury have stunning death 
rates compared to the one who does not (51.2 vs 5.5 percent; hazard ratio 4.26, CI 95% 1.92-
9.49).6,7 
Diagnosis of myocardial injury should be suspected in patients with COVID-19 
infections if there are new findings of troponin elevation, global or regional left ventricular 
wall motion abnormalities, unexplained cardiac arrhythmias, or ECG changes (prominently 
diffuse ST elevation). 
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Based on the etiology, myocardial injury in COVID-19 infection may be differentiated 
into myocarditis, hypoxic injury, stress cardiomyopathy, ischemic injury caused by cardiac 
microvascular damage, epicardial coronary artery disease, and systemic inflammatory response 
syndrome (cytokine storm).8 Histopathologic tissue done in a case of COVID-19 patient 
showed that COVID-19 is not responsible for direct myocardial damage.9 However, further 
studies should be done to ensure the cause of myocarditis in COVID-19 infection. 
Heart failure should be accounted as one of the complications (49% in patients who 
died and 3% in recovered patients) of COVID-19 patients.10 The risk factors of cardiac 
complications include older age, pre-existing cardiovascular diseases, and severe pneumonia.  
It is still unclear whether heart failure were caused by exacerbation of pre-existing conditions, 
such as left ventricular dysfunction, or due to new cardiomyopathy caused by COVID-19.1,4 
 Serum troponin level should be checked routinely in patients hospitalized with COVID-
19 infection.11 Mild troponin elevation (< 99th upper reference limit) usually happens in patient 
who survived after hospitalization, early moderate troponin elevation (exceed the 99th upper 
reference limit) usually seen in patients with suspected myocarditis and stress cardiomyopathy, 
progressive troponin elevation with rising accelerated in the second week hospitalization 
should warrant for impending mortality due to cytokine storm (median 18.5 days after 
symptom onset).1,4 
  
 
Arrhythmia and Conduction System Disease in COVID-19 Patients 
Most of the time, COVID-19 infection does not cause the symptoms of arrhythmia 
directly.11,12 Mostly, the patient will be tachycardic (7.3% of cases) due to demand-related 
conditions such as fever or shortness of breath.1,13 There are notably several conditions that 
might trigger arrhythmia in COVID-19 patients: Myocarditis or myocardial ischemia, hypoxia 
or shock, electrolyte imbalance, receiving QT-prolonging drugs, and have underlying disease 
of Brugada disease.  
Prevention should be done by electrocardiography (ECG) examination. Although 12 
lead ECG is recommended, a single lead recording may suffice to minimize staff exposure to 
the patient. The thing to note is mainly the QRS-T morphology. From the QRS-T morphology, 
we may determine the possibility of myocarditis, acute coronary syndrome, and the baseline of 
QT interval.13 Frequent monitoring of QT interval should be done especially if COVID-19 
drugs are started (Figure 1); mainly azithromycin (risk of Torsades de pointes 4.7-6.7%) and 
chloroquine (or hydroxychloroquine) which may increase the risk of QT prolongation and the 
risk of Torsades de Pointes (TdP).14 This was caused by activation blockage of potassium 
channel IKr (hERG/KV11.1) and both treatments metabolized by CYP3A4 which delay its 
clearance in the plasma.15,16 
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Figure 1. Algorithm to prevent TdP or SCD in COVID-19 patients 
TdP: Torsades des Pointes; SCD: Sudden Cardiac Death 
Modified from: Wu CI, et al20 
 
Patients with known Brugada syndrome may need special attention regarding 
temperature management. Paracetamol use for fever control will be paramount in preventing 
the risk of ventricular arrhythmia due to fever in COVID-19 patients with Brugada Syndrome. 
In several cases, implantable cardiac defibrillator might be imperative to prevent sudden 
cardiac death in patient with Brugada Syndrome especially in the midst of COVID-19 
pandemic.16 
 Viral myocarditis is known to be the main causes of arrhythmogenicity causing any 
degree of atrioventricular block, bundle branch blocks, or tachyarrhythmias.17,18 This 
especially in the acute phase due to direct cytopathic effect, gap junction dysfunction, and 
abnormal calcium pump along with channel function.19 Treatment relies on the type of 
arrhythmias such as amiodarone, beta-blocker, or even transcatheter ablation if the 
tachyarrhythmia was drug-resistant.20,21 
 
Coronary Artery Disease and Acute Coronary Syndrome in COVID-19 Patients 
 About 4.2 to 25 percent of patients with COVID-19 infections had coronary artery 
disease (CAD).22 Although COVID-19 might not directly cause CAD, it might worsen in 
patient with pre-existing CAD due to increase in metabolic demand which in turn trigger type 
II myocardial ischemia (MI).23,24 
 Although type II MI dominates the presentation of acute coronary syndrome in COVID-
19 patients, type I MI still exists and requires optimal management. In patients infected with 
COVID-19, establishing the diagnosis of ST Elevation Myocardial Infarct (STEMI) may prove 
to be difficult. This is related to the possibility of concomitant myocarditis in COVID-19 
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patients which is one of the differential diagnosis of STEMI patients. Although, finding 
regional wall motion abnormalities through point of care bedside echocardiography in the acute 
setting might prove to be beneficial for determining the diagnosis.22 
 Management of STEMI revascularization strategy might shift from primary 
percutaneous coronary intervention to the more liberal use of fibrinolytic therapy. This is 
recommended as to reduce the viral exposure to health care providers. Although, usually within 
3 to 24 hours the patient may still require coronary angiography as part of pharmacoinvasive 
strategy. But this might differ based on the availability from each center. Similar approach also 
applies in Non-ST Elevation Acute Coronary Syndrome (NSTEACS) when urgent 
catheterization is considered. The resource limitation and risk of exposure to medical personnel 
should also be taken into account.25,26 
 
Cardiogenic Shock 
Although the available data showed the incidence of profound cardiogenic shock is low 
in COVID-19,27 the clinical presentation of COVID-19 can resemble a cardiogenic condition, 
therefore it is important to consider cardiogenic or mixed causes of the clinical manifestations. 
To distinguish ARDS and cardiogenic causes, the Berlin criteria considers symptom onset, 
bilateral pulmonary opacities, and lack of volume overload. Serum brain natriuretic peptide 
(BNP) and echocardiography can further distinguish the two. If a clear diagnosis could not be 
made yet, pulmonary artery catheterization can be considered when deciding for the use of 
extracorporeal membrane oxygenation (ECMO) or other invasive management to achieve the 
highest benefit for patients and the community.1 In patients with acute systolic heart failure 
and COVID-19, when inotropic support fails, intra-aortic balloon pump is recommended 
because of the relatively low maintenance needed.28 
 
DRUG THERAPY AND COVID-19: INTERACTION AND CARDIOVASCULAR  
IMPLICATIONS 
 
Curative Treatment of COVID-19 and The Cardiovascular Implication 
Hydroxychloroquine, Chloroquine, and Azithromycin have been declared as potential 
prophylaxis or treatment for COVID-19 infection. Hydroxychloroquine act on the entry and 
post-entry stages of COVID-19 infection, likely via effects on endosomal pH and the resulting 
under-glycosylation of ACE-2 receptors that are required for viral entry.29 Both of chloroquine 
and hydroxychloroquine are known to prolong QT interval. They can provoke pro-arrhythmia 
via mechanisms beyond the block of IKr implicated in usual cases of torsade de pointes.
30,31 
Azithromycin, a frequently used macrolide antibiotic, lacks strong pharmacodynamic evidence 
of IKr inhibition. There is limited data evaluating the safety of combination therapy. Regarding 
a quasi-randomized comparative study by Barbosa et al (2020), stated that hydroxychloroquine 
did not appear to have a beneficial effect on meaningful clinical outcome measures of mortality, 
lymphopenia reconstitution, neutrophil-to-lymphocyte ratio, or risk for intubation.32 
The AHA, the ACC and the HRS guidance for health care professionals includes 
additional mechanisms to reduce the risk of arrhythmias if hydroxychloroquine, chloroquine, 
and/ or azithromycin should be administered.33 
1. Electrocardiographic/QT interval monitoring (Figure 1). 
a. Withhold hydroxychloroquine and azithromycin in patients with baseline QT 
prolongation (e.g. QTc ≥500 msec) or with known congenital long QT syndrome. 
b. Monitor cardiac rhythm and QT interval; withdrawal of hydroxychloroquine and 
azithromycin if QTc exceeds a present threshold of 500 msec. 
On
i e
 F
r t
This article has been accepted for publication but has not been through the copyediting, typesetting, pagination and proofreading process.
doi: 10.30701/ijc.1008
c. In patients critically ill with COVID-19 infection, frequent caregiver contact may need 
to be minimized, so optimal electrocardiographic interval and rhythm monitoring may 
not be possible. 
2. Correction of hypokalemia >4mEq/L and hypomagnesemia >2mg/dL. 
3. Avoid other QTc prolonging agents whenever feasible 
According to Tisdale et al (2016), there are risk factors associated with QTc 
prolongation, which have been developed into a risk score tool (Table 1) that takes age, sex, 
diuretic use, potassium level, baseline QTc, acute myocardial infarction, use of QTc prolonging 
drugs, sepsis and heart failure into account.33 
Another issue to be underlined is the possible drug-drug interaction with anticoagulants 
which are routinely used in acute coronary syndrome and as the newest emerging clinical 
evidence, prophylaxis for pulmonary embolism in COVID-19 patients. The use of novel oral 
anticoagulant (NOAC) and vitamin k-antagonist should be withheld due to the drug-drug 
interaction to azithromycin and hydroxychloroquine. Instead, low molecular weight heparin 
(LMWH), factor Xa inhibitor, and unfractionated heparin should be the drug of choice.34 
 
 
Renin-Angiotensin-Aldosterone System Inhibitors and Aggravating the Disease 
Virulence Issues  
There has been a concern regarding the safety of Angiotensin Converting Enzyme 
inhibitor (ACEi) and Angiotensin II Receptor Blockers (ARBs) during the ongoing COVID-
19 pandemic. These agents upregulate expression of ACE-2 in various tissues, including on 
cardiomyocytes.35 Since SARS-CoV2 binds to ACE-2 to gain entry into human cells, there is 
a potentially increased risk of developing COVID-19 or developing more severe disease in 
patients who are already on background treatment with ACEi or ARB.  
Unfortunately, data showing the effects of ACEi, ARBs, and other RAAS inhibitors on 
lung-specific expression of ACE-2 in experimental animal models and in humans are lacking.35 
At the same time, abrupt withdrawal of RAAS inhibitors in high-risk patients, including those 
who have heart failure or myocardial infarction or hypertension, may result in clinical 
instability and adverse health outcomes. Therefore, several leading professional societies have 
strongly urged to not discontinue clinically-indicated ACEi/ARBs therapy in COVID-19 
patients.36,37 
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 Table 1. Risk score for identifying patients at greatest risk of QTc interval prolongation. 
(modified from Tisdale et al.)38 
 
Conclusion 
Cardiovascular disease may present as one of the comorbidities for COVID-19 infection or 
even as a complication of COVID-19. ACE inhibition, as the holy grail of heart failure therapy; 
although debatable regarding its use in COVID-19 infection, it was recommended and proven 
beneficial in COVID-19 patients with hypertension or heart failure. Furthermore, the use of 
COVID-19 medications has the risk of  malignant arrhythmia and drug-drug interactions. 
Those facts should raise the awareness of cardiovascular disease in the midst of COVID-19 
pandemic infection. 
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